Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer
Nonmetastatic Castration-Resistant Prostate Cancer
Cancer of the Prostate

Interventions: Drug: Placebo
Drug: Enzalutamide

Registration Number: NCT02003924

Lead Sponsor: Pfizer

Brief Summary: The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Detailed Description: Not available

Recruitment & Eligibility

Status: ACTIVE_NOT_RECRUITING

Sex: Male

Target Recruitment: 1402

Inclusion Criteria

Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features;
Ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior bilateral orchiectomy (medical or surgical castration);
Testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening;
Progressive disease on androgen deprivation therapy at enrollment;
PSA and the screening PSA assessed by the central laboratory (central PSA) should be ≥ 2 µg/L (2 ng/mL:
PSA doubling time ≤ 10 months;
No prior or present evidence of metastatic disease;
Asymptomatic prostate cancer;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Estimated life expectancy ≥ 12 months.

Exclusion Criteria

Prior cytotoxic chemotherapy;
Use of hormonal therapy or biologic therapy for prostate cancer (other than approved bone targeting agents and GnRH agonist/antagonist therapy) or use of an investigational agent within 4 weeks of randomization;
Known or suspected brain metastasis or active leptomeningeal disease;
History of another invasive cancer within 3 years of randomization;
Absolute neutrophil count < 1000/μL, platelet count < 100,000/μL, or hemoglobin < 10 g/dL (6.2 mmol/L) at screening;
Total bilirubin ≥ 1.5 times the upper limit of normal;
Creatinine > 2 mg/dL (177 µmol/L) at screening;
Albumin < 3.0 g/dL (30 g/L) at screening;
History of seizure or any condition that may predispose to seizure;
Clinically significant cardiovascular disease;
Gastrointestinal disorder affecting absorption;
Major surgery within 4 weeks of randomization;
Hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene;
Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of data, in the opinion of the investigator or medical monitor.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Sugar pill manufactured to mimic enzalutamide 40 mg capsule
Enzalutamide	Enzalutamide	160 mg by mouth once daily

Primary Outcome Measures

Name	Time	Method
Metastasis Free Survival (MFS)	From randomization until radiographic progression at any time, or death within 112 days of treatment discontinuation, whichever occurred first (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	MFS:time from randomization to first date of radiographic progression (RP) (by Blinded independent central radiology review \[BICR\]) at any time or death within 112 days of treatment discontinuation without evidence of RP.RP for bone disease:appearance of 1 or more metastatic lesions on bone scan.RP for soft tissue disease:per Response Evaluation Criteria in Solid Tumors,\[RECIST 1.1\])-at least a 20 percent (%) increase in the sum of diameters of target lesions,taking as reference the smallest sum on study (includes the baseline sum if smallest on study).Participants who did not have MFS event at the time of analysis data cut-off (28 June 2017) were censored at date of last assessment showing no objective evidence of RP prior to skeletal-related event or two or more consecutive missed tumor assessments. Participants who were randomized but later confirmed to have metastatic disease before randomization were censored on date of randomization. Analysis was based on Kaplan-Meier estimates.

Secondary Outcome Measures

Name	Time	Method
Time to Prostate-Specific Antigen (PSA) Progression	From randomization until first PSA progression (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Time to PSA progression was defined as the time from randomization to the date of first PSA value demonstrating progression, which was subsequently confirmed. For participants with PSA decline at Week 17, PSA progression was defined according to Prostate Cancer Working Group 2 (PCWG2) guidelines as the date that a 25% or greater increase and an absolute increase of 2 nanograms per milliliter (ng/mL) above the nadir (or baseline for participants with no PSA decline by Week 17) was documented, which was confirmed by a second consecutive value obtained at least 3 weeks or later. Participants without confirmed PSA progression at the time of analysis were right censored at the date of last PSA assessment before the analysis data cut-off date for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.
Time to First Use of New Antineoplastic Therapy	From randomization until first use of new antineoplastic therapy(until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Time to first use of new antineoplastic therapy was defined as the time from randomization to first use of new antineoplastic for prostate cancer. Participants not starting treatment with a new antineoplastic therapy at the time of analysis were right censored at the date of last assessment before the analysis data cutoff date for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.
Overall Survival	From randomization until death (up to a maximum of 68.8 months)	Overall survival (OS) was defined as the time (in months) from randomization to death from any cause. For participants who were alive at the time of the analysis data cutoff, OS time was censored at the last date the participant was known to be alive or analysis data cutoff date, whichever was earlier. Participants with no post baseline survival information were censored on the date of randomization. Analysis was based on Kaplan-Meier estimates.
Time to Pain Progression	From randomization until onset of pain progression (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Pain was assessed using the score from the Brief Pain Inventory-Short Form (BPI-SF) question 3: "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours." Time to this event was defined as the time from randomization to onset of pain progression, where pain progression was defined as a 2-point or more increase from baseline in the question 3 score. Participants without observed pain progression at the time of analysis were right censored at the date of last pain assessment for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.
Time to First Use of Cytotoxic Chemotherapy	From randomization up to the first use of cytotoxic chemotherapy (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Time to first use of cytotoxic chemotherapy was defined as the time from randomization to the first use of cytotoxic chemotherapy for prostate cancer. Participants not starting treatment with a cytotoxic chemotherapy for prostate cancer at the time of analysis were right censored at the date of last assessment before the analysis data cutoff date for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.
Chemotherapy-Free Disease Specific Survival	From randomization up to first use of cytotoxic chemotherapy for prostate cancer or death due to prostate cancer (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Chemotherapy-free disease-specific survival was defined as the time from randomization to first use of cytotoxic chemotherapy for prostate cancer or death due to prostate cancer as assessed by the investigator. Participants not starting treatment with a cytotoxic chemotherapy or not known to have died due to prostate cancer at the time of analysis were right censored at the date of last assessment before the analysis data cutoff date for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.
Chemotherapy-Free Survival	From randomization up to first use of cytotoxic chemotherapy for prostate cancer or death due to any cause (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Chemotherapy-free survival was defined as the time from randomization to first use of cytotoxic chemotherapy for prostate cancer or death due to any cause. Participants not starting treatment with a cytotoxic chemotherapy or not known to have died at the time of analysis were censored at the date of last assessment before the analysis data cutoff date for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.
Percentage of Participants With Prostate Specific Antigen (PSA) Response	From randomization until first PSA progression (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	PSA response was calculated at each visit as a decline from baseline in PSA (ng/mL) to the maximal PSA response with thresholds at 50% and 90%. Additionally, PSA response was assessed as a decline to undetectable levels, where undetectable level was defined as below the limit of quantification of the centrally assessed PSA results (the lower limit of quantification was 0.02 ng/mL). PSA response was confirmed by a second consecutive value at least 3 weeks later.
Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Global Score	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The FACT-P questionnaire is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess prostate-related symptoms. Each item was rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score which ranged from 0 to 156 where higher scores represented better quality of life.
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 50	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 50 are reported. Question 50 was following: "To what extent were you interested in sex?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 51	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 51 are reported. Question 51 was following: "To what extent were you sexually active (with or without intercourse)?"
Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Mobility Domain Score	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the mobility questionnaire are reported.
Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Self-Care Domain Score	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the self-care questionnaire are reported.
Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Usual Activities Domain Score	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the usual activities questionnaire are reported.
Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Pain/Discomfort Domain Score	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the pain/discomfort questionnaire are reported.
Number of Participants With European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Anxiety/ Depression Domain Score	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the anxiety/depression questionnaire are reported.
European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Overall Health Status Visual Analog Score (VAS)	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 31	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 31 are reported. Question 31 was following: "Have you had to urinate frequently during the day?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 32	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 32 are reported. Question 32 was following: "Have you had to urinate frequently at night?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 33	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 33 are reported. Question 33 was following: "When you felt the urge to pass urine, did you have to hurry to get to the toilet?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 34	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 34 are reported. Question 34 was following: "Was it difficult for you to get enough sleep, because you needed to get up frequently at night to urinate?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 35	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 35 are reported. Question 35 was following: "Have you had difficulty going out of the house because you needed to be close to a toilet?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 36	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 36 are reported. Question 36 was following: "Have you had any unintentional release (leakage) of urine?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 37	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 37 are reported. Question 37 was following: "Did you have pain when you urinated?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 38	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 38 are reported. Question 38 was following: "Has wearing an incontinence aid been a problem for you?". This question was answered by only those participants who wore incontinence aid.
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 45	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 45 are reported. Question 45 was following: "Have you had sore or enlarged nipples or breasts?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 39	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 39 are reported. Question 39 was following: "Have your daily activities been limited by your urinary problems?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 40	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 40 are reported. Question 40 was following: "Have your daily activities been limited by your bowel problems?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 41	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 41 are reported. Question 41 was following: "Have you had any unintentional release (leakage) of stools?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 42	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 42 are reported. Question 42 was following: "Have you had blood in your stools?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 43	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 43 are reported. Question 43 was following: "Did you have a bloated feeling in your abdomen?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 44	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 44 are reported. Question 44 was following: "Did you have hot flushes?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 46	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 46 are reported. Question 46 was following: "Have you had swelling in your legs or ankles?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 47	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 47 are reported. Question 47 was following: "Has weight loss been a problem for you?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 48	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 48 are reported. Question 48 was following: "Has weight gain been a problem for you?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 49	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 49 are reported. Question 49 was following: "Have you felt less masculine as a result of your illness or treatment?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 52	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 52 are reported. Question 52 was following: "To what extent was sex enjoyable for you?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 53	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 53 are reported. Question 53 was following: "Did you have difficulty getting or maintaining an erection?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 54	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 54 are reported. Question 54 was following: "Did you have ejaculation problems (e.g, dry ejaculation)?"
Number of Participants With European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Prostate 25 (QLQ-PR25) Module Score for Question 55	Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177	The EORTC QLQ-PR25, a module of the EORTC QLQ-30 questionnaire was used to assess the quality of life. It consisted of 25 questions (Question 31 to 55) distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Participants answered each of these questions using 4 point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Number of participants with various responses to the question 55 are reported. Question 55 was following: "Have you felt uncomfortable about being sexually intimate?"
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment-emergent AE (TEAE) was defined as an AE that occurred from the date and time of the first dose of study drug through the date of last dose +30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first). AEs included both non-serious adverse events (AEs) and SAEs.
Number of Participants With Treatment-Emergent Adverse Events Greater Than or Equal to Grade 3, Based on National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE), Version 4.0	From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. As per NCI CTCAE, Grade 3 events =medically significant but not immediately life-threatening, unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment, Grade 4 events =participant to be in imminent danger of death. Grade 5 events =death. A treatment-emergent AE (TEAE) was defined as an AE that occurred from the date and time of the first dose of study drug through the date of last dose +30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first).Number of participants with AEs of any of the Grade 3 or above (Grade 4, 5) were reported.
Number of Participants With Discontinuations From Study Treatment Due to Adverse Events (AEs)	From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both non-serious adverse events (AEs) and SAEs.
Number of Participants With Increase of 2 or More National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) (Version 4.0) Toxicity Grades Above Baseline - Hematology	From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Hematology parameters: Haemoglobin (grams per liter \[g/L\]); leukocytes (log 10 raised to power 9 per liter \[10\9/L\]); lymphocytes (log 10 raised to power 6 per liter \[10\6/L\]); neutrophils (log 10 raised to power 6 per liter \[10\6/L\]); platelets (log 10 raised to power 9 per litre \[10\9/L\]).
Number of Participants With Increase of 2 or More National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) (Version 4.0) Toxicity Grades Above Baseline - Chemistry	From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Chemistry parameters: Alanine aminotransferase (units per liter \[U/L\]); albumin (g/L); alkaline phosphatase (U/L); bilirubin (micromoles per liter \[umol/L\]); calcium (millimoles per liter \[mmol/L\]); creatine kinase (U/L); creatinine (umol/L); glucose, magnesium, phosphate, potassium, sodium (mmol/L).
Number of Participants With Clinically Significant Vital Signs	From first dose of study drug to the last dose + 30 days (or the day before initiation of a new antineoplastic treatment, whichever occurred first) (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)	Vital signs included Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and heart rate.

Trial Locations

Locations (387): Urological Associates of Southern Arizona, PC
🇺🇸
Tucson, Arizona, United States
Ronald Reagan UCLA Medical Center
🇺🇸
Los Angeles, California, United States
UCLA Clark Urology Center
🇺🇸
Los Angeles, California, United States
University of California, Irvine Medical Center
🇺🇸
Orange, California, United States
Urology Associates of San Luis Obispo, a Medical Group, Inc
🇺🇸
San Luis Obispo, California, United States
Urology Associates, P.C.
🇺🇸
Englewood, Colorado, United States
c/o Lynn Buchwalder
🇺🇸
New Haven, Connecticut, United States
C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven
🇺🇸
New Haven, Connecticut, United States
Smilow Cancer Center at Yale New Haven-Hospital
🇺🇸
New Haven, Connecticut, United States
Yale New Haven Hospital
🇺🇸
New Haven, Connecticut, United States
Yale University School of Medicine
🇺🇸
New Haven, Connecticut, United States
Lakeland Regional Cancer Center
🇺🇸
Lakeland, Florida, United States
Urology of Indiana, LLC
🇺🇸
Carmel, Indiana, United States
First Urology, PSC
🇺🇸
Jeffersonville, Indiana, United States
IU Health Arnett Cancer Care
🇺🇸
Lafayette, Indiana, United States
Kansas City Urology Care, PA
🇺🇸
Overland Park, Kansas, United States
GU Research Network/ Wichita Urology Group
🇺🇸
Wichita, Kansas, United States
Chesapeake Urology Research Associates
🇺🇸
Baltimore, Maryland, United States
University of Michigan Health System
🇺🇸
Ann Arbor, Michigan, United States
Michigan Institute of Urology
🇺🇸
Troy, Michigan, United States
GU Research Network
🇺🇸
Omaha, Nebraska, United States
Brooklyn Urology Research Group
🇺🇸
Brooklyn, New York, United States
Premier Medical Group of the Hudson Valley
🇺🇸
Newburgh, New York, United States
Duke University Medical Center
🇺🇸
Cary, North Carolina, United States
Carolina Urology Partners, PLLC
🇺🇸
Huntersville, North Carolina, United States
Gaston Medical Associates
🇺🇸
Gastonia, North Carolina, United States
Duke Women's Cancer Care Raleigh
🇺🇸
Raleigh, North Carolina, United States
Clinical Research Solutions
🇺🇸
Middleburg Heights, Ohio, United States
Oregon Urology Institute
🇺🇸
Springfield, Oregon, United States
Lancaster Urology
🇺🇸
Lancaster, Pennsylvania, United States
Carolina Urologic Research Center
🇺🇸
Myrtle Beach, South Carolina, United States
Vanderbilt University Medical Center, Dept. of Urologic Surgery
🇺🇸
Nashville, Tennessee, United States
Vanderbilt University Medical Center, The Urologic Clinic
🇺🇸
Nashville, Tennessee, United States
Urology San Antonio
🇺🇸
San Antonio, Texas, United States
Urology of Virginia, PLLC
🇺🇸
Virginia Beach, Virginia, United States
COIBA(Centro de Oncologia e Investigacion Buenos Aires)
🇦🇷
Berazategui, Buenos Aires, Argentina
Centro Medico Austral(OMI)
🇦🇷
Caba, Buenos Aires, Argentina
Centro de Urologia
🇦🇷
Caba, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
🇦🇷
Caba, Buenos Aires, Argentina
Sanatorio Parque
🇦🇷
Rosario, Santa FE, Argentina
Instituto De Oncologia De Rosario
🇦🇷
Rosario, Santa FE, Argentina
Clinica Universidad Reina Fabiola
🇦🇷
Cordoba, Argentina
Hospital Privado Centro Medico de Cordoba
🇦🇷
Cordoba, Argentina
Centro Oncologico Riojano Integral (CORI)
🇦🇷
La Rioja, Argentina
The Canberra Hospital
🇦🇺
Garran, Australian Capital Territory, Australia
Border Medical Oncology Research Unit
🇦🇺
Albury, New South Wales, Australia
The Border Cancer Hospital Dispensary
🇦🇺
Albury, New South Wales, Australia
The Border Cancer Hospital
🇦🇺
Albury, New South Wales, Australia
Sydney cancer centre
🇦🇺
Concord, New South Wales, Australia
Epic pharmacy
🇦🇺
Lismore, New South Wales, Australia
North Coast Cancer Institute
🇦🇺
Lismore, New South Wales, Australia
Macquarie University Hospital
🇦🇺
North Ryde, New South Wales, Australia
Macquarie University
🇦🇺
North Ryde, New South Wales, Australia
Epic Pharmacy Port Macquarie base hospital
🇦🇺
Port Macquarie, New South Wales, Australia
Mid North Coast Cancer Institute
🇦🇺
Port Macquarie, New South Wales, Australia
Royal North Shore Hospital
🇦🇺
St Leonards, New South Wales, Australia
The Tweed Hospital
🇦🇺
Tweed Heads, New South Wales, Australia
Australian Clinical Trials
🇦🇺
Wahroonga, New South Wales, Australia
Sydney Adventist Hospital
🇦🇺
Wahroonga, New South Wales, Australia
Calvary Mater Newcastle
🇦🇺
Waratah, New South Wales, Australia
Westmead Hospital
🇦🇺
Westmead, New South Wales, Australia
Icon Cancer Care Wesley
🇦🇺
Auchenflower, Queensland, Australia
River City Pharmacy - APHS
🇦🇺
Auchenflower, Queensland, Australia
Icon Cancer Care Chermside
🇦🇺
Chermside, Queensland, Australia
Icon Cancer Care South Brisbane
🇦🇺
South Brisbane, Queensland, Australia
Integrated Clinical Oncology Network (ICON)
🇦🇺
South Brisbane, Queensland, Australia
Icon Cancer Care Southport
🇦🇺
Southport, Queensland, Australia
Tasman Oncology Research Pty Ltd
🇦🇺
Southport, Queensland, Australia
Princess Alexandra Hospital
🇦🇺
Woolloongabba, Queensland, Australia
Adelaide Cancer Centre
🇦🇺
Kurralta Park, South Australia, Australia
Ashford Cancer Centre Research
🇦🇺
Kurralta park, South Australia, Australia
Cancer Care SA Pty Ltd
🇦🇺
Kurralta Park, South Australia, Australia
Tenpharm Pty Ltd trading as EPIC Pharmacy Tennyson
🇦🇺
Kurralta Park, South Australia, Australia
Box Hill Hospital (Eastern health)
🇦🇺
Box Hill, Victoria, Australia
Eastern Clinical Research Unit (Eastern Health)
🇦🇺
Box Hill, Victoria, Australia
Cabrini Hospital Brighton
🇦🇺
Brighton, Victoria, Australia
Monash Medical Centre
🇦🇺
Clayton, Victoria, Australia
Austin Health, Austin Hospital
🇦🇺
Heidelberg, Victoria, Australia
Cabrini Hospital Malvern
🇦🇺
Malvern, Victoria, Australia
Cabrini Hospital- Education and Research Precinct
🇦🇺
Malvern, Victoria, Australia
Peter MacCallum Cancer Centre
🇦🇺
Melbourne, Victoria, Australia
Sunshine Hospital
🇦🇺
St Albans, Victoria, Australia
Krankenhaus Barmherzige Schwestern Linz, Abteilung Radiologie
🇦🇹
Linz, Upper Austria, Austria
Krankenhaus Barmherzige Schwestern Linz, Abteilung Urologie
🇦🇹
Linz, Upper Austria, Austria
St. Vincent's Hospital, PET - CT Center
🇦🇹
Linz, Upper Austria, Austria
Isotopix, Ambulatorium fuer Nuklearmedizin
🇦🇹
Vienna, Austria
Medizinische Universitaet Wien, Universitaetsklinik fuer Innere Medizin I
🇦🇹
Vienna, Austria
Diagnosezentrum Meidling GesmbH
🇦🇹
Vienna, Austria
Algemeen Ziekenhuis Groeninge
🇧🇪
Kortrijk, West-vlaanderen, Belgium
Clinique Universitaire de Bruxelles Hopital Erasme
🇧🇪
Bruxelles, Belgium
Vzw Algemeen Ziekenhuis Maria Middelares
🇧🇪
Gent, Belgium
Universitaire Ziekenhuizen Leuven
🇧🇪
Leuven, Belgium
Centre Hospitalier Universitaire de Liege, Site du Sart-Tilman
🇧🇪
Liege, Belgium
Hospital Sao Rafael
🇧🇷
Salvador, Bahia, Brazil
Liga Paranaense de Combate ao cancer / Hospital Erasto Gaertner
🇧🇷
Curitiba, Parana, Brazil
Associacao Hospital de Caridade de Ijui
🇧🇷
Ijui, RIO Grande DO SUL, Brazil
Hospital da Cidade de Passo Fundo
🇧🇷
Passo Fundo, RIO Grande DO SUL, Brazil
Hospital de Clinicas de Porto Alegre
🇧🇷
Porto Alegre, RIO Grande DO SUL, Brazil
CLINIONCO - Clinica de Oncologia de Porto Alegre Ltda.
🇧🇷
Porto Alegre, RIO Grande DO SUL, Brazil
Hospital Sao Lucas da PUCRS
🇧🇷
Porto Alegre, RIO Grande DO SUL, Brazil
Instituto D'Or de Pesquisa e Ensino (IDOR)
🇧🇷
Rio de Janeiro, RJ, Brazil
Hospital Amaral Carvalho - Fundacao Dr. Amaral Carvalho
🇧🇷
Jau, SAO Paulo, Brazil
Fundacao Dr. Amaral Carvalho
🇧🇷
Jau, SAO Paulo, Brazil
Fundacao Dr.Amaral Carvalho
🇧🇷
Jau, SAO Paulo, Brazil
Hospital Israelita Albert Einstein
🇧🇷
Sao Paulp, SAO Paulo, Brazil
Hospital das Clinicas da Faculdade de Ciencias Medicas da UNICAMP
🇧🇷
Campinas, SP, Brazil
Centro de Estudos e Pesquisas em Hematologia e Oncologia (CEPHO)
🇧🇷
Santo Andre, SP, Brazil
IAMSPE-Inst. de Assist. ao Servidor Publico Estadual
🇧🇷
Sao Paulo, SP, Brazil
Hospital Universitario Pedro Ernesto - UERJ
🇧🇷
Rio de Janeiro, Brazil
Oncologia Rede D'Or
🇧🇷
Rio de Janeiro, Brazil
Tom Baker Cancer Centre
🇨🇦
Calgary, Alberta, Canada
Cross Cancer Institute
🇨🇦
Edmonton, Alberta, Canada
Vancouver Prostate Centre
🇨🇦
Vancouver, British Columbia, Canada
Manitoba Prostate Centre CancerCare Manitoba
🇨🇦
Winnipeg, Manitoba, Canada
NS Health Authority, Queen Elizabeth II Health Sciences Centre
🇨🇦
Halifax, Nova Scotia, Canada
The Male/Female Health and Research Centre
🇨🇦
Barrie, Ontario, Canada
McMaster Institute of Urology @ St. Joseph's Healthcare Hamilton
🇨🇦
Hamilton, Ontario, Canada
Urology Associates / Urologic Medical Research
🇨🇦
Kitchener, Ontario, Canada
London Regional Cancer Program - Victoria Hospital, London Health Sciences Centre(LHSC)
🇨🇦
London, Ontario, Canada
Urology Reasearch - Victoria Hospital, London Health Sciences Centre(LHSC)
🇨🇦
London, Ontario, Canada
SunnyBrook Health Sciences Centre
🇨🇦
Toronto, Ontario, Canada
University Health Network- Princess Margaret Cancer Centre
🇨🇦
Toronto, Ontario, Canada
Urology South Shore Research
🇨🇦
Greenfield Park, Quebec, Canada
Centre Hospitalier de l'Université de Montréal
🇨🇦
Montreal, Quebec, Canada
McGill University Health Centre
🇨🇦
Montreal, Quebec, Canada
CHU de Quebec
🇨🇦
Quebec, Canada
Fundacion Arturo Lopez Perez
🇨🇱
Santiago, Chile
Centro de Investigaciones Clinicas Vina del Mar
🇨🇱
Santiago, Chile
Instituto Clinico Oncologico del Sur (ICOS)
🇨🇱
Temuco, Chile
Instituto Oncologico Ltda.
🇨🇱
Vina del Mar, Chile
Centro de Investigaciones Clinicas
🇨🇱
Vina del Mar, Chile
Peking University First Hospital
🇨🇳
Beijing, Beijing, China
Beijing Cancer Hospital
🇨🇳
Beijing, Beijing, China
Peking University Third Hospital
🇨🇳
Beijing, Beijing, China
Beijing Hospital
🇨🇳
Beijing, Beijing, China
Peking Union Medical College Hospital
🇨🇳
Beijing, Beijing, China
Chongqing Cancer Hospital
🇨🇳
Chongqing, Chongqing, China
The First Affiliated Hospital of Guangzhou Medical University
🇨🇳
Guangzhou, Guangdong, China
Zhongnan Hospital of Wuhan University
🇨🇳
Wuhan, Hubei, China
Office of Hongqian Guo
🇨🇳
Nanjing, Jiangsu, China
Jiangsu Cancer Hospital
🇨🇳
Nanjing, Jiangsu, China
Jiangsu Province Hospital
🇨🇳
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University
🇨🇳
Suzhou, Jiangsu, China
Wuxi People's Hospital
🇨🇳
Wuxi, Jiangsu, China
Qingdao Municipal Hospital (East Hospital)
🇨🇳
Qingdao, Shandong, China
Fudan University Shanghai Cancer Center
🇨🇳
Shanghai, Shanghai, China
Huashan Hospital Fudan University
🇨🇳
Shanghai, Shanghai, China
Shanghai First People's Hospital
🇨🇳
Shanghai, Shanghai, China
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳
Shanghai, Shanghai, China
Shanghai Changhai Hospital
🇨🇳
Shanghai, Shanghai, China
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳
Xi'an, Shanxi, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
🇨🇳
Hangzhou, Zhejiang, China
The First Affiliated Hosptial of Wenzhou Medical University
🇨🇳
Wenzhou, Zhejiang, China
UNIMED Medical Institute Limited
🇨🇳
Hong Kong, China
The Second Hospital of Tianjin Medical University
🇨🇳
Tianjin, China
Rigshospitalet 7521
🇩🇰
Copenhagen, Norrebro, Denmark
Copenhagen Prostate Cancer Center
🇩🇰
Copenhagen, N, Denmark
Aarhus University Hospital
🇩🇰
Arhus N, Denmark
Rigshospitalet
🇩🇰
Copenhagen, Denmark
Frederiksberg Hospital
🇩🇰
Frederiksberg, Denmark
Herlev Hospital
🇩🇰
Herlev, Denmark
Odense University Hospital
🇩🇰
Odense C, Denmark
Vejle Sygehus
🇩🇰
Vejle, Denmark
Docrates Syopasairaala
🇫🇮
Helsinki, Finland
Helsingin yliopistollinen keskussairaala, Meilahden sairaala
🇫🇮
Helsinki, Finland
Oulun yliopistollinen sairaala
🇫🇮
Oulu, Finland
Satakunnan keskussairaala
🇫🇮
Pori, Finland
Tampereen yliopistollinen Sairaala
🇫🇮
Tampere, Finland
Hopitaux Universitaires de Strasbourg - Hopital Civil
🇫🇷
STRASBOURG Cedex, Alsace, France
Centre Paul Strauss
🇫🇷
Strasbourg, Bas-rhin, France
Clinique Sainte Anne
🇫🇷
Strasbourg, Bas-rhin, France
Societe MIM, Clinique Sainte Anne
🇫🇷
Strasbourg, Bas-rhin, France
Institut Curie
🇫🇷
Paris Cedex, Paris, France
Centre Hospitalier Lyon Sud
🇫🇷
Pierre Benite, France
Institut Gustave Roussy
🇫🇷
Villejuif Cedex, VAL DE Marne, France
Institut de Cancerologie de l'Ouest - Paul Papin
🇫🇷
Angers Cedex 2, France
Institut Sainte Catherine
🇫🇷
Avignon, France
Institut Bergonie
🇫🇷
Bordeaux Cedex, France
Urologic Oncology Department- Institut Bergonie - Centre regional de Lutte contre le Cancer
🇫🇷
Bordeaux Cedex, France
Cabinet de Radiologie
🇫🇷
Brest, France
CHU Brest Hopital Morvan
🇫🇷
Brest, France
Clinique pasteur Lancroze
🇫🇷
Brest, France
Clinique Pasteur-Lanroze
🇫🇷
Brest, France
CHRU de Brest
🇫🇷
Brest, France
Hopital Pasteur
🇫🇷
Colmar Cedex, France
Hopitaux Civils de Colmar
🇫🇷
Colmar, France
Centre Regional de lutte Contre le Cancer Georges Francois Leclerc
🇫🇷
Dijon, France
Clinique Victor Hugo
🇫🇷
Le Mans, France
Hopital Calude Huriez - CHU Lille
🇫🇷
Lille, France
Hopital Edouard Herriot - CHU Lyon
🇫🇷
Lyon Cedex 03, France
Centre Leon Berard
🇫🇷
Lyon Cedex, France
Centre de Medecine Nucleaire LUMEN
🇫🇷
Lyon, France
Hopital Nord
🇫🇷
Marseille, France
ICM Val D'Aurelle
🇫🇷
Montpellier Cedex, France
Hopital Europeen Georges Pompidou
🇫🇷
Paris, France
CHU Poitiers - Hopital la Miletrie
🇫🇷
Poitiers, France
Institut de Cancerologie de I'Ouest - Rene Gauducheau
🇫🇷
Saint-Herblain Cedex, France
Clinique Pasteur - CIMOF
🇫🇷
Toulouse Cedex 3, France
Clinique Pasteur- Service Imagerie et Radiologie
🇫🇷
Toulouse Cedex 3, France
Clinique Pasteur
🇫🇷
Toulouse Cedex 3, France
IUCT-Oncopole
🇫🇷
Toulouse Cedex 9, France
Institut Claudius Regaud
🇫🇷
Toulouse, France
Studienpraxis Urologie
🇩🇪
Nuertingen, Baden-wuerttemberg, Germany
Universitatsmedizin Mannheim, Medizinische Fakultat Mannheim der Universitat Heidelberg
🇩🇪
Mannheim, Baden-wurttemberg, Germany
MVZ Zentrum fuer Diagnostische Radiologie und Nuklearmedizin Braunschweig GmbH
🇩🇪
Braunschweig, Niedersachsen, Germany
Staedtisches Klinikum Braunschweig
🇩🇪
Braunschweig, Niedersachsen, Germany
Hannover Medical School
🇩🇪
Hannover, Niedersachsen, Germany
Medizinische Hochschule Hannover
🇩🇪
Hannover, Niedersachsen, Germany
RWTH University Aachen
🇩🇪
Aachen, Nordrhein-westfalen, Germany
Uniklinik der RWTH Aachen
🇩🇪
Aachen, Nordrhein-westfalen, Germany
Clinic of Radiology
🇩🇪
Aachen, Nordrhein-westfalen, Germany
Universitaetsklinikum Carl Gustav Carus an der TU Dresden
🇩🇪
Dresden, Saxony, Germany
Charite, Campus Benjamin Franklin
🇩🇪
Berlin, Germany
Charite, Universitaetsmedizin Berlin
🇩🇪
Berlin, Germany
Martini-Klinik am UKE GmbH
🇩🇪
Hamburg, Germany
Diagnostikzentrum Esslingen
🇩🇪
Kirchheim, Germany
University General Hospital of Heraklion, Urology Clinic
🇬🇷
Heraklion, Crete, Greece
General Hospital of Athens"Korgialeneio-Benakeio EES".Urology Clinic
🇬🇷
Athens, Greece
General Hospital of Athens "Alexandra", Therapeutic Clinic
🇬🇷
Athens, Greece
University General Hospital of Larissa, Urology Department
🇬🇷
Larissa, Greece
University General Hospital of Patras, Oncology Department, Internal Medicine Clinic
🇬🇷
Patra, Greece
General Hospital" Papageorgiou",B' Univ.Urology Clinic
🇬🇷
Thessaloniki, Greece
Queen Mary Hospital
🇭🇰
Hong Kong, Hong Kong
Tuen Mun Hospital
🇭🇰
Hong Kong, Hong Kong
Prince of Wales Hospital
🇭🇰
Shatin, Hong Kong
Laboratorio Medicina Nucleare-Ospedale G.B. Morgagni-Pierantoni
🇮🇹
Forli, FC, Italy
Farmacia, Azienda Socio Sanitaria Territoriale di Cremona
🇮🇹
Cremona, Italy
Medicina Nucleare, Azienda Socio Sanitaria Territoriale di Cremona
🇮🇹
Cremona, Italy
Servizio di Radiologia, Azienda Socio Sanitaria Territoriale di Cremona
🇮🇹
Cremona, Italy
Struttura Complessa di Oncologia, Azienda Socio Sanitaria Territoriale di Cremona
🇮🇹
Cremona, Italy
U.O. di Oncologia, Ospedale Civile Degli Infermi
🇮🇹
Faenza (RA), Italy
U.O. di Radiologia, Ospedale Civile degli Infermi
🇮🇹
Faenza (RA), Italy
U.O. di Oncologia, Ospedale Civile Umberto I
🇮🇹
Lugo (RA), Italy
U.O. di Radiologia, Ospedale Civile Umberto I
🇮🇹
Lugo (RA), Italy
Laboratorio Farmaci Antiblastici
🇮🇹
Meldola (FC), Italy
U.O. Oncologia Medica
🇮🇹
Meldola (FC), Italy
UO Radiologia
🇮🇹
Meldola (FC), Italy
Dipartimento di Radiologia, Ospedale San Raffaele
🇮🇹
Milano, Italy
Servizio di Farmacia, Ospedale San Raffaele
🇮🇹
Milano, Italy
U.O. di Medicina Nucleare e Centro PET, Ospedale San Raffaele
🇮🇹
Milano, Italy
U.O. di Urologia, Ospedale San Raffaele
🇮🇹
Milano, Italy
Farmacia Studi Clinici e Sperimentali, Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹
Milano, Italy
S.C. di Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹
Milano, Italy
S.C. Diagnostica Radiologica 2, Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹
Milano, Italy
Divisione di Radiologia, Istituto Europeo di Oncologia
🇮🇹
Milano, Italy
Reparto Oncologia Medica Urogenitale e Cervico Facciale, Istituto Europeo di Oncologia
🇮🇹
Milano, Italy
Servizio Farmacia, Istituto Europeo di Oncologia
🇮🇹
Milano, Italy
Farmacia Interna, Azienda Ospedaliero-Universitaria Policlinico di Modena
🇮🇹
Modena, Italy
Medicina Nucleare, Azienda Ospedaliero-Universitaria Policlinico di Modena
🇮🇹
Modena, Italy
Radiologia I, Azienda Ospedaliero-Universitaria Policlinico di Modena
🇮🇹
Modena, Italy
U.O.S.C. di Oncologia Medica, A.O.R.N. "A. Cardarelli"
🇮🇹
Napoli, Italy
Farmacia Ospedaliera, AOU San Luigi Gonzaga
🇮🇹
Orbassano (TO), Italy
SCDU Oncologia Medica II Pad, AOU San Luigi Gonzaga
🇮🇹
Orbassano (TO), Italy
SCDU Radiodiagnostica, AOU San Luigi Gonzaga
🇮🇹
Orbassano (TO), Italy
SS Medicina Nucleare, AOU San Luigi Gonzaga
🇮🇹
Orbassano (TO), Italy
Farmacia, Istituto Oncologico Veneto (IOV)
🇮🇹
Padova, Italy
IRCCS - Istituto Oncologico Veneto (IOV), UOC Oncologia Medica 1
🇮🇹
Padova, Italy
Medicina Nucleare, Istituto Oncologico Veneto (IOV)
🇮🇹
Padova, Italy
UOC Radiodiagnostica Oncologica, Istituto Oncologico Veneto (IOV)
🇮🇹
Padova, Italy
Dipartimento di Onco-Ematologia Ospedale Santa Maria delle Croci
🇮🇹
Ravenna, Italy
Servizio di Farmacia, AUSL di Ravenna
🇮🇹
Ravenna, Italy
Servizio di Radiologia, AUSL di Ravenna
🇮🇹
Ravenna, Italy
Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica
🇮🇹
Roma, Italy
U.O. di Oncologia Medica, Ospedale Santa Chiara
🇮🇹
Trento, Italy
U.O. Farmacia, Ospedale Santa Chiara
🇮🇹
Trento, Italy
U.O. Radiologia, Ospedale Santa Chiara
🇮🇹
Trento, Italy
National Cancer Center
🇰🇷
Goyang-si, Gyeonggi-do, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷
Hwasun-gun, Jeonnam, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷
Incheon, Korea, Republic of
Seoul National University Hospital
🇰🇷
Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷
Seoul, Korea, Republic of
Asan Medical Center
🇰🇷
Seoul, Korea, Republic of
Gangnam Severance Hospital, Yonsei University Health System
🇰🇷
Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷
Seoul, Korea, Republic of
Universiti Kebangsaan Malaysia Medical Centre
🇲🇾
Cheras, Kuala Lumpur, Malaysia
Sarawak General Hospital
🇲🇾
Kuching, Sarawak, Malaysia
Subang Jaya Medical Centre Sdn. Bhd.
🇲🇾
Subang Jaya, Selangor Darul Ehsan, Malaysia
Hospital Kuala Lumpur
🇲🇾
Kuala Lumpur, Malaysia
University Malaya Medical Centre
🇲🇾
Kuala Lumpur, Malaysia
Maastricht University Medical Centre
🇳🇱
Maastricht, AZ, Netherlands
Catharina Ziekenhuis
🇳🇱
Eindhoven, Noord-brabant, Netherlands
Netherlands Cancer Institute
🇳🇱
Amsterdam, Netherlands
Albert Schweitzer Ziekenhuis
🇳🇱
Dordrecht, Netherlands
University Medical Center Groningen
🇳🇱
Groningen, Netherlands
Radboud University Nijmegen Medical Centre
🇳🇱
Nijmegen, Netherlands
Canterbury District Health Board
🇳🇿
Christchurch, Canterbury, New Zealand
Palmerston North Hospital
🇳🇿
Palmerston North, Manawatu, New Zealand
Cancer and Blood Research
🇳🇿
Auckland, New Zealand
Waikato Urology Research LTD
🇳🇿
Hamilton, New Zealand
Uniwersyteckie Centrum Kliniczne
🇵🇱
Gdansk, Poland
UROMEDYK, Poradnia Urologiczna
🇵🇱
Kielce, Poland
Malopolskie Centrum Medyczne s.c.
🇵🇱
Krakow, Poland
Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ
🇵🇱
Lublin, Poland
Wojewodzki Szpital Specjalistyczny im. Janusza. Korczaka
🇵🇱
Slupsk, Poland
Profesorskie Centrum Medyczne Optimum
🇵🇱
Wroclaw, Poland
Centrum Medyczne Melita Medical
🇵🇱
Wroclaw, Poland
Wro Medica
🇵🇱
Wroclaw, Poland
Lexmedica
🇵🇱
Wroclaw, Poland
Federal State Budgetary Institution "N.N. Blokhin Russian Cancer Research Center"
🇷🇺
Moscow, Russian Federation
P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research
🇷🇺
Moscow, Russian Federation
State Budgetary Healthcare Institution City Multifield Hospital No.2
🇷🇺
Saint-Petersburg, Russian Federation
SBEI HPE "First Pavlov State Medical University of St. Petersburg" of
🇷🇺
Saint-Petersburg, Russian Federation
Saint-Petersburg State Budgetary Healthcare Institution "Hospital for Veterans of War"
🇷🇺
Saint-Petersburg, Russian Federation
SBHI "Saint-Petersburg clinical scientific
🇷🇺
Saint-Petersburg, Russian Federation
SBEI of HPE "Bashkir State Medical University" of MoH of the RF
🇷🇺
Ufa, Russian Federation
Clinical Center Of Serbia, Clinic of Urology
🇷🇸
Belgrade, Serbia
Clinical Center "Dr Dragisa Misovic -Dedinje", Clinic of Urology
🇷🇸
Belgrade, Serbia
Clinical Center "Bezanijska Kosa", Department of Urology
🇷🇸
Belgrade, Serbia
Clinical Center Zemun
🇷🇸
Belgrade, Serbia
National University Hospital
🇸🇬
Singapore, Singapore
National Cancer Centre Singapore
🇸🇬
Singapore, Singapore
Fakultna nemocnica s poliklinikou F.D. Roosevelta
🇸🇰
Banska Bystrica, Slovakia
Institut nuklearnej a molekularnej mediciny
🇸🇰
Kosice, Slovakia
Bratislavske radiodiagnosticke centrum, a.s.
🇸🇰
Bratislava, Slovakia
CUIMED, s.r.o., Urologicka ambulancia
🇸🇰
Bratislava, Slovakia
Vychodoslovensky onkologicky ustav, a.s.
🇸🇰
Kosice, Slovakia
Univerzitna nemocnica Martin
🇸🇰
Martin, Slovakia
IZOTOPCENTRUM, s.r.o.
🇸🇰
Nitra, Slovakia
Jessenius-diagnosticke centrum, a.s.
🇸🇰
Nitra, Slovakia
UROEXAM spol. s r.o. urologicka ambulancia
🇸🇰
Nitra, Slovakia
Alfamedis, s.r.o.
🇸🇰
Presov, Slovakia
MILAB s.r.o., UROCENTRUM
🇸🇰
Presov, Slovakia
Vivamed, s.r.o
🇸🇰
Presov, Slovakia
UVN SNP - FN Ruzomberok, Pracovisko Nuklearnej mediciny CCSR
🇸🇰
Ruzomberok, Slovakia
Fakultna nemocnica s Poliklinikou Skalica a.s
🇸🇰
Skalica, Slovakia
GAMMALAB, spol. s.r.o., Oddelenie nuklearnej mediciny
🇸🇰
Trnava, Slovakia
GAMMALAB, spol.s.r.o., Oddelenie nuklearnej mediciny
🇸🇰
Trnava, Slovakia
KK MED s.r.o.
🇸🇰
Zilina, Slovakia
Fakultna nemocnica s poliklinikou Zilina, Urologicke oddelenie
🇸🇰
Zilina, Slovakia
Hospital Clinico Universitario de Santiago de Compostela
🇪🇸
Santiago de Compostela, A Coruna, Spain
Hospital Universitari Son Espases,
🇪🇸
Palma de Mallorca, Baleares, Spain
Hospital Germans Trias i Pujol
🇪🇸
Badalona, Barcelona, Spain
ALTAHIA. Xarxa Assistencial Universitaria de Manresa
🇪🇸
Manresa, Barcelona, Spain
Hospital Universitario Parc Tauli
🇪🇸
Sabadell, Barcelona, Spain
ICO Girona-Hospital Universitari de Girona Dr. Josep Trueta
🇪🇸
Gerona, Cataluna, Spain
Hospital de Navarra
🇪🇸
Pamplona, Navarra, Spain
Complejo Hospitalario Universitario A Coruna
🇪🇸
A Coruna, Spain
Hospital Del Mar
🇪🇸
Barcelona, Spain
Cetir Centre Medic, S.L.
🇪🇸
Barcelona, Spain
Hospital Clinic de Barcelona
🇪🇸
Barcelona, Spain
Hospital Universitario de la Princesa
🇪🇸
Madrid, Spain
MD Anderson Cancer Center
🇪🇸
Madrid, Spain
Hospital Universitario 12 de octubre
🇪🇸
Madrid, Spain
Urologmottagningen
🇸🇪
Stockholm, Sweden
Diagnostiskt centrum for bild- och funktionsmedicin
🇸🇪
Malmo, Sweden
Urologiska Kliniken
🇸🇪
Örebro, Sweden
Apoteket AB Kliniska Provningar Molnlycke
🇸🇪
Molnlycke, Sweden
Karolinska Universitetssjukhuset
🇸🇪
Solna, Sweden
Urologkliniken
🇸🇪
Umea, Sweden
Chang Gung Medical Fundation, Chiayi Branch(Chiayi Chang Gung Memorial Hospital)
🇨🇳
Chiayi County, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳
Kaohsiung, Taiwan
Kaohsiung Veterans General Hospital
🇨🇳
Kaohsiung, Taiwan
Chang Gung Medical Fundation,Kaohsiung (Kaohsiung Chang Gung Memorial Hospital)
🇨🇳
Kaohsiung, Taiwan
Chang Gung Memorial Hospital, Keelung Branch (Keelung Chang Gung Memorial Hospital)
🇨🇳
Keelung City, Taiwan
China Medical University Hospital
🇨🇳
Taichung, Taiwan
Taichung Veterans General Hospital
🇨🇳
Taichung, Taiwan
Chi Mei Medical Centre
🇨🇳
Tainan City, Taiwan
National Taiwan University Hospital
🇨🇳
Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳
Taipei, Taiwan
Chang-Gung Memorial Hospital at Linkuo
🇨🇳
Taoyuan County, Taiwan
Maharaj Nakorn Chiang Mai Hospital
🇹🇭
Muang, Chiang MAI, Thailand
Songklanagarind hospital
🇹🇭
Hat Yai, Songkla, Thailand
King Chulalongkorn Memorial Hospital, Chulalongkorn University
🇹🇭
Bangkok, Thailand
Rajavithi Hospital
🇹🇭
Bangkok, Thailand
Cukurova Universitesi Tip Fakultesi
🇹🇷
Adana, Turkey
Hacettepe Universitesi Tip Fakultesi
🇹🇷
Ankara, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi
🇹🇷
Istanbul, Turkey
Izmir Bozyaka Egitim Arastirma Hastanesi
🇹🇷
Izmir, Turkey
Celal Bayar Universitesi Tip Fakultesi
🇹🇷
Manisa, Turkey
RCI Chernivtsi Regional Clinical Hospital
🇺🇦
Chernivtsi, Ukraine
CI Dnipropetrovsk I.I. Mechnykov RCH, Department of Urology #2
🇺🇦
Dnipropetrovsk, Ukraine
CHI V.I.Shapoval RCC of Urology and Nephrology, Dep. Of Urology#4
🇺🇦
Kharkiv, Ukraine
Kyiv City Clinical Hospital #3, Department of Urology
🇺🇦
Kyiv, Ukraine
Central City Clinical Hospital, City Oncological Center
🇺🇦
Uzhgorod, Ukraine
CI Zaporizhzhia Regional Clinical Hospital, Dep. Of Urology,
🇺🇦
Zaporizhzhia, Ukraine
East and North Hertfordshire NHS Trust
🇬🇧
Northwood, Middlesex, United Kingdom
Belfast Health and Social Care Trust
🇬🇧
Belfast, Northern Ireland, United Kingdom
Royal Marsden NHS Foundation Trust
🇬🇧
Sutton, Surrey, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
🇬🇧
Newcastle upon Tyne, Tyne and Wear, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
🇬🇧
Birmingham, United Kingdom
University Hospitals Bristol NHS Foundation Trust
🇬🇧
Bristol, United Kingdom
Cambridge University Hospitals NHS Foundation Trust
🇬🇧
Cambridge, United Kingdom
University College Hospitals NHS Trust
🇬🇧
London, United Kingdom
Imperial College Healthcare NHS Trust
🇬🇧
London, United Kingdom
University College London Hospitals NHS Foundation Trust
🇬🇧
London, United Kingdom
The Christie NHS Foundation Trust
🇬🇧
Manchester, United Kingdom
Oxford University Hospitals NHS Trust
🇬🇧
Oxford, United Kingdom